GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » Gross Profit

Atreca (Atreca) Gross Profit : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Atreca Gross Profit?

Atreca's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Atreca's gross profit for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Atreca's gross profit for the three months ended in Sep. 2023 was $0.00 Mil. Atreca's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Atreca's Gross Margin % for the quarter that ended in Sep. 2023 was N/A%.

Atreca had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage


Atreca Gross Profit Historical Data

The historical data trend for Atreca's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Gross Profit Chart

Atreca Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Get a 7-Day Free Trial - - - - -

Atreca Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atreca's Gross Profit

For the Biotechnology subindustry, Atreca's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atreca's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atreca's Gross Profit distribution charts can be found below:

* The bar in red indicates where Atreca's Gross Profit falls into.



Atreca Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Atreca's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Atreca's Gross Profit for the quarter that ended in Sep. 2023 is calculated as

Gross Profit (Q: Sep. 2023 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Atreca's Gross Margin % for the quarter that ended in Sep. 2023 is calculated as

Gross Margin % (Q: Sep. 2023 )=Gross Profit (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Atreca  (OTCPK:BCEL) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Atreca had a gross margin of N/A% for the quarter that ended in Sep. 2023 => No sustainable competitive advantage


Atreca Gross Profit Related Terms

Thank you for viewing the detailed overview of Atreca's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Atreca (Atreca) Business Description

Traded in Other Exchanges
Address
835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Executives
Felix Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz officer: VP of Finance C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould officer: Chief Scientific Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini director, officer: Chief Strategy Officer C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney officer: General Counsel & Secretary ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop officer: Chief Medical Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma director C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg officer: Chief Scientific Officer 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson director 500 SAGINAW DRIVE, REDWOOD CITY CA 94063